Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody.

Chakraborty A, Tannenbaum S, Rordorf C, Lowe PJ, Floch D, Gram H, Roy S.

Clin Pharmacokinet. 2012 Jun 1;51(6):e1-18. doi: 10.2165/11599820-000000000-00000. Review.

2.

Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS).

Kuemmerle-Deschner JB, Ramos E, Blank N, Roesler J, Felix SD, Jung T, Stricker K, Chakraborty A, Tannenbaum S, Wright AM, Rordorf C.

Arthritis Res Ther. 2011 Feb 28;13(1):R34. doi: 10.1186/ar3266.

3.

Sotrastaurin and everolimus pharmacokinetics after single-dose coadministration.

Kovarik JM, Bartlett M, Rordorf C, Antunes MC, Winter S, Marbach P, van Marle S.

Int J Clin Pharmacol Ther. 2010 Feb;48(2):103-8.

PMID:
20137762
4.

In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes.

Lachmann HJ, Lowe P, Felix SD, Rordorf C, Leslie K, Madhoo S, Wittkowski H, Bek S, Hartmann N, Bosset S, Hawkins PN, Jung T.

J Exp Med. 2009 May 11;206(5):1029-36. doi: 10.1084/jem.20082481. Epub 2009 Apr 13.

5.

The PKC inhibitor AEB071 may be a therapeutic option for psoriasis.

Skvara H, Dawid M, Kleyn E, Wolff B, Meingassner JG, Knight H, Dumortier T, Kopp T, Fallahi N, Stary G, Burkhart C, Grenet O, Wagner J, Hijazi Y, Morris RE, McGeown C, Rordorf C, Griffiths CE, Stingl G, Jung T.

J Clin Invest. 2008 Sep;118(9):3151-9. doi: 10.1172/JCI35636.

6.

The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis.

Alten R, Gram H, Joosten LA, van den Berg WB, Sieper J, Wassenberg S, Burmester G, van Riel P, Diaz-Lorente M, Bruin GJ, Woodworth TG, Rordorf C, Batard Y, Wright AM, Jung T.

Arthritis Res Ther. 2008;10(3):R67. doi: 10.1186/ar2438. Epub 2008 Jun 5.

7.

Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor.

Rordorf CM, Choi L, Marshall P, Mangold JB.

Clin Pharmacokinet. 2005;44(12):1247-66. Review.

PMID:
16372823
8.

Lumiracoxib does not affect the ex vivo antiplatelet aggregation activity of low-dose aspirin in healthy subjects.

Jermany J, Branson J, Schmouder R, Guillaume M, Rordorf C.

J Clin Pharmacol. 2005 Oct;45(10):1172-8.

PMID:
16172182
9.

Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients.

Hartmann SN, Rordorf CM, Milosavljev S, Branson JM, Chales GH, Juvin RR, Lafforgue P, Le Parc JM, Tavernier CG, Meyer OC.

Ann Pharmacother. 2004 Oct;38(10):1582-7. Epub 2004 Aug 31.

PMID:
15340127
10.

No influence of moderate hepatic impairment on the pharmacokinetics of lumiracoxib, an oral COX-2 selective inhibitor.

Kalbag J, Yeh CM, Milosavljev S, Lasseter K, Oberstein S, Rordorf C.

Pharmacol Res. 2004 Aug;50(2):181-6.

PMID:
15177307
11.

Concomitant administration of lumiracoxib and a triphasic oral contraceptive does not affect contraceptive activity or pharmacokinetic profile.

Kalbag J, Elder C, Scott G, Wang Y, Milosavljev S, Leese P, Caldwell J, Rordorf C.

J Clin Pharmacol. 2004 Jun;44(6):646-54.

PMID:
15145973
12.

Pharmacokinetics of lumiracoxib in plasma and synovial fluid.

Scott G, Rordorf C, Reynolds C, Kalbag J, Looby M, Milosavljev S, Weaver M, Huff JP, Ruff DA.

Clin Pharmacokinet. 2004;43(7):467-78.

PMID:
15139795
13.

Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects.

Mangold JB, Gu H, Rodriguez LC, Bonner J, Dickson J, Rordorf C.

Drug Metab Dispos. 2004 May;32(5):566-71.

PMID:
15100180
14.

Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib.

Scott G, Vinluan Reynolds C, Milosavljev S, Langholff W, Shenouda M, Rordorf C.

Clin Pharmacokinet. 2004;43(5):341-8.

PMID:
15080766
15.

Assessment of lumiracoxib bioavailability from targeted sites in the human intestine using remotely activated capsules and gamma scintigraphy.

Wilding IR, Connor AL, Carpenter P, Rordorf C, Branson J, Milosavljev S, Scott G.

Pharm Res. 2004 Mar;21(3):443-6.

PMID:
15070094
16.

Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: An integrated study.

Atherton C, Jones J, McKaig B, Bebb J, Cunliffe R, Burdsall J, Brough J, Stevenson D, Bonner J, Rordorf C, Scott G, Branson J, Hawkey CJ.

Clin Gastroenterol Hepatol. 2004 Feb;2(2):113-20.

PMID:
15017615
17.

Lumiracoxib: pharmacokinetic and pharmacodynamic profile when coadministered with fluconazole in healthy subjects.

Scott G, Yih L, Yeh CM, Milosavljev S, Laurent A, Rordorf C.

J Clin Pharmacol. 2004 Feb;44(2):193-9.

PMID:
14747429
18.

Influence of delayed initiation of cyclosporine on everolimus pharmacokinetics in de novo renal transplant patients.

Kovarik JM, Dantal J, Civati G, Rizzo G, Rouilly M, Bettoni-Ristic O, Rordorf C.

Am J Transplant. 2003 Dec;3(12):1576-80.

19.

Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure.

Kovarik JM, Eisen H, Dorent R, Mancini D, Vigano M, Rouilly M, Hsu CH, Rordorf C.

J Heart Lung Transplant. 2003 Oct;22(10):1117-25.

PMID:
14550821
20.

Gastroduodenal tolerability of lumiracoxib vs placebo and naproxen: a pilot endoscopic study in healthy male subjects.

Rordorf C, Kellett N, Mair S, Ford M, Milosavljev S, Branson J, Scott G.

Aliment Pharmacol Ther. 2003 Sep 1;18(5):533-41.

21.

Pharmacokinetics of an everolimus-cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation.

Kovarik JM, Kaplan B, Silva HT, Kahan BD, Dantal J, McMahon L, Berthier S, Hsu CH, Rordorf C.

Am J Transplant. 2003 May;3(5):606-13.

22.

Clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmacokinetics.

Kovarik JM, Noe A, Berthier S, McMahon L, Langholff WK, Marion AS, Hoyer PF, Ettenger R, Rordorf C.

J Clin Pharmacol. 2003 Feb;43(2):141-7.

PMID:
12616666
23.

Effect of rifampin on apparent clearance of everolimus.

Kovarik JM, Hartmann S, Figueiredo J, Rouilly M, Port A, Rordorf C.

Ann Pharmacother. 2002 Jun;36(6):981-5.

PMID:
12022896
24.

Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range.

Kovarik JM, Kaplan B, Tedesco Silva H, Kahan BD, Dantal J, Vitko S, Boger R, Rordorf C.

Transplantation. 2002 Mar 27;73(6):920-5.

PMID:
11923693
25.

Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants.

Kovarik JM, Hartmann S, Figueiredo J, Rordorf C, Golor G, Lison A, Budde K, Neumayer HH.

Pharmacotherapy. 2002 Feb;22(2):154-9.

PMID:
11837553
26.

Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus.

Kovarik JM, Hartmann S, Hubert M, Berthier S, Schneider W, Rosenkranz B, Rordorf C.

J Clin Pharmacol. 2002 Feb;42(2):222-8.

PMID:
11831546
27.

Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: a clinically relevant pharmacokinetic interaction.

Kovarik JM, Kalbag J, Figueiredo J, Rouilly M, Frazier OL, Rordorf C.

J Clin Pharmacol. 2002 Jan;42(1):95-9.

PMID:
11808830
28.

Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment.

Kovarik JM, Sabia HD, Figueiredo J, Zimmermann H, Reynolds C, Dilzer SC, Lasseter K, Rordorf C.

Clin Pharmacol Ther. 2001 Nov;70(5):425-30.

PMID:
11719728
29.

Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications.

Kovarik JM, Hsu CH, McMahon L, Berthier S, Rordorf C.

Clin Pharmacol Ther. 2001 Sep;70(3):247-54.

PMID:
11557912
30.

Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.

Kovarik JM, Kahan BD, Kaplan B, Lorber M, Winkler M, Rouilly M, Gerbeau C, Cambon N, Boger R, Rordorf C; Everolimus Phase 2 Study Group.

Clin Pharmacol Ther. 2001 Jan;69(1):48-56.

PMID:
11180038
31.

Neoepitope immunoassay: an assay for human interleukin 1 beta based on an antibody induced conformational change.

Towbin H, Erard F, van Oostrum J, Schmitz A, Rordorf C.

J Immunoassay. 1996 Nov;17(4):353-69.

PMID:
8957765
32.
33.

Methotrexate action in rheumatoid arthritis: stimulation of cytokine inhibitor and inhibition of chemokine production by peripheral blood mononuclear cells.

Seitz M, Loetscher P, Dewald B, Towbin H, Rordorf C, Gallati H, Baggiolini M, Gerber NJ.

Br J Rheumatol. 1995 Jul;34(7):602-9.

PMID:
7670776
34.

CGP 47969A: effect on collagen induced arthritis in DBA/1 mice.

Geiger T, Rordorf C, Cosenti-Vargas A, Ferrini PG, Widler L, Glatt M, Vosbeck K.

J Rheumatol. 1994 Nov;21(11):1992-7.

PMID:
7869300
35.

Monoclonal antibody based enzyme-linked and chemiluminescent assays for the human interleukin-1 receptor antagonist. Application to measure hIL-1ra levels in monocyte cultures and synovial fluids.

Towbin H, Schmitz A, van Oostrum J, Seitz M, Dewald B, Zingel O, Motz J, Vosbeck K, Rordorf C.

J Immunol Methods. 1994 Mar 29;170(1):125-35.

PMID:
8157985
36.

Interferon-gamma overcomes the glucocorticoid-mediated and the interleukin-4-mediated inhibition of interleukin-1 beta synthesis in human monocytes.

Geiger T, Arnold J, Rordorf C, Henn R, Vosbeck K.

Lymphokine Cytokine Res. 1993 Oct;12(5):271-8.

PMID:
8260535
37.

Neutralization of interleukin-1 beta activity in vivo with a monoclonal antibody alleviates collagen-induced arthritis in DBA/1 mice and prevents the associated acute-phase response.

Geiger T, Towbin H, Cosenti-Vargas A, Zingel O, Arnold J, Rordorf C, Glatt M, Vosbeck K.

Clin Exp Rheumatol. 1993 Sep-Oct;11(5):515-22.

PMID:
8275587
38.

The influence of major trauma on the regulatory levels of interleukin-1 (IL-1) and IL-2 in human mononuclear leukocytes.

Faist E, Schinkel C, Zimmer S, Kremer JP, Alkan S, Rordorf C, von Donnersmarck H, Schildberg FW.

Zentralbl Chir. 1993;118(7):420-31.

PMID:
8372524
39.

Pharmacokinetics and immunomodulatory effects on monocytes during prolonged therapy with liposomal muramyltripeptide.

Landmann R, Obrist R, Denz H, Ludwig C, Frost H, Wesp M, Rordorf C, Towbin H, Gygax D, Tarcsay L, et al.

Biotherapy. 1993;7(1):1-12.

PMID:
8068481
40.

Recombinant human C5a induces transcription but not translation of interleukin 1 beta mRNA in human monocytes.

Geiger T, Rordorf C, Galakatos N, Seligmann B, Henn R, Lazdins J, Erard F, Vosbeck K.

Lymphokine Cytokine Res. 1992 Feb;11(1):55-63.

PMID:
1576247
41.

Recombinant human C5a induces transcription but not translation of interleukin-1 beta mRNA in human monocytes.

Geiger T, Rordorf C, Galakatos N, Seligmann B, Henn R, Lazdins J, Vosbeck K.

Res Immunol. 1992 Jan;143(1):117-23.

PMID:
1565840
43.

Human immunodeficiency virus type 1 (HIV-1) infection of the central nervous system: an evaluation of cytokines in cerebrospinal fluid.

Gallo P, Frei K, Rordorf C, Lazdins J, Tavolato B, Fontana A.

J Neuroimmunol. 1989 Jul;23(2):109-16.

PMID:
2656753
44.

Connective tissue deposits in MRL/1 mice.

Pataki A, Rordorf CH.

Ann Rheum Dis. 1987 Jan;46(1):85-6. No abstract available.

45.

Arthritis in MRL/LPR mice and in collagen II sensitized DBA-1 mice and their use in pharmacology.

Rordorf C, Pataki A, Nogues V, Schlager F, Feige U, Glatt M.

Int J Tissue React. 1987;9(4):341-7.

PMID:
3623829
46.
47.

The acute-phase response in (NZB X NZW)F1 and MRL/l MICE.

Rordorf C, Schnebli HP, Baltz ML, Tennent GA, Pepys MB.

J Exp Med. 1982 Oct 1;156(4):1268-73.

Supplemental Content

Loading ...
Support Center